Accelrys, Inc.  

(Public, NASDAQ:ACCL)   Watch this stock  
Find more results for ACCL
8.63
-0.02 (-0.23%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.46 - 8.63
52 week 7.44 - 9.98
Open 8.60
Vol / Avg. 113,754.00/224,165.00
Mkt cap 481.95M
P/E     -
Div/yield     -
EPS -0.25
Shares 55.85M
Beta 0.95
Inst. own 89%
Jul 29, 2013
Q2 2013 Accelrys, Inc. Earnings Release Add to calendar
May 29, 2013
Accelrys, Inc. at Craig-Hallum Capital Group Institutional Investor Conference Add to calendar
May 21, 2013
Accelrys, Inc. at B. Riley & Co. Investor Conference
May 15, 2013
Accelrys, Inc. at JMP Securities' Research Conference
Apr 30, 2013
Q1 2013 Accelrys, Inc. Earnings Conference Call
Apr 29, 2013
Q1 2013 Accelrys, Inc. Earnings Release
Mar 19, 2013
Accelrys, Inc. at Sidoti Emerging Growth Institutional Investor Forum
Mar 6, 2013
Q4 2012 Accelrys, Inc. Earnings Release
Feb 26, 2013
Q4 2012 Accelrys, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -13.59% -6.40%
Operating margin -15.34% -12.77%
EBITD margin - 7.50%
Return on average assets -5.71% -2.56%
Return on average equity -9.56% -4.23%
Employees 647 -
Carbon Disclosure Rating - -

Address

Suite 100, 10188 Telesis Court
SAN DIEGO, CA 92121-3752
United States - Map
+1-858-7995000 (Phone)
+1-858-7995100 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Accelrys, Inc. develops and commercializes scientific informatics software products and services for industries and organizations. The Company�s product lines include Pipeline Pilot, Accelrys Enterprise Research and Development (R & D) Platform; Computer Aided Design Modeling and Simulation Software; Enterprise Lab Notebook; Lab Execution Systems; Content Databases, and Data Management & Informatics Software. The Company�s customers include pharmaceutical, biotechnology and other life science companies, as well as companies that are in the energy, chemicals, aerospace and consumer packaged goods markets. Its software and service solutions are used by its customers� scientists, biologists, chemists and information technology professionals in order to aggregate, mine, integrate, analyze, simulate, manage and interactively report scientific data. In January 2013, the Company completed the purchase of Vialis.

Officers and directors

Christopher van Ingen Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Scipio M. Carnecchia President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Michel A. Piraino Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Mathew A. Hahn Ph.D. Chief Technology Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
David R. Mersten Senior Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Mollie Hunter Senior Vice President - Global Sales & Services
Age: 53
Bio & Compensation  - Reuters
Leif Pedersen Senior Vice President - Marketing, Product Management and Corporate Development
Bio & Compensation  - Reuters
Judith Ohrn Hicks Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Anil Thakur Senior Vice President - Software Development
Age: 48
Bio & Compensation  - Reuters
Kenneth L. Coleman Jr. Independent Director
Age: 60
Bio & Compensation  - Reuters